Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Posted on by Pencis

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Stanford University School of Medicine | United States

Author Profile

Scopus

Orcid id

📚 Biography: Dr. Stavros Melemenidis

🎓 Education

  • DPhil in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2010-2015)
    • Mentors: Prof. Nicola Sibson, Prof. Ruth Muschel
    • Thesis: Development of molecular targeted imaging methods for the detection of lung metastasis and angiogenesis
  • M.Sc. in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2009-2010)
  • M.Sc. in Radiometrics – University of Liverpool, Dept. Physics, Liverpool, UK (2008-2009)
  • B.Sc. in Physics: Medical Applications – University of Liverpool, Dept. Physics, Liverpool, UK (2005-2008)
  • A.Eng. in PC Systems and Peripheral Equipment – IIEK Neapoleos, Technical College, Thessaloniki, Greece (1998-2000)
  • Cert. Medical Physics – UCLA, Dept. Radiation Oncology, Los Angeles, CA, USA (2022-2023)

🏢 Current Position

  • Director of Pre-clinical Radiotherapy – Dept. of Radiation Oncology, Stanford University (Jan 2023-present)
  • Research Scientist – Div. of Radiation Therapy, Stanford University (Feb 2020-present)

🔬 Research Experience & Skills

  • Stanford University, Dept. Radiation Oncology, Stanford, CA
    • Director of Pre-clinical Radiotherapy Core (Jun 2023-present)
      • Calibration of preclinical orthovoltage irradiators
      • Monthly and annual quality checks for dosimetric consistency
      • Innovation in animal radiation shielding via 3D design and additive manufacturing
    • Basic Life Research Scientist at Div. of Radiation Therapy (Jun 2020-present)
      • Pioneering preclinical ultra-high dose-rate (FLASH) irradiation experiments
      • Specializing in 3D-designed radiation shielding for animal safety
      • Expertise in dosimetry using radiochromic film and ion chambers
      • Development of animal models involving tumor implantation and microsurgical techniques
    • Postdoctoral Fellow (Feb 2016-Jun 2020)
      • Advisor: Edward E. Graves
      • Led development of in vivo mouse tumor models integrating imaging, radiotherapy, and immunotherapy
      • Specialized in ultrasound-guided injection techniques
      • Conducted research into immune cell migration with a focus on macrophage imaging
      • Evaluated radioprotective strategies for healthy tissue through drug development
    • Postdoctoral Fellow at University of Oxford, Dept. Radiation Oncology (Jan 2015-Sep 2015)
      • Advisor: Nicola R. Sibson
      • Designed and evaluated innovative imaging probes for metastasis detection and angiogenesis visualization
      • Developed dual MRI/PET probe for metastasis and MRI probe for angiogenesis
      • Managed international research collaboration with Duke University

📜 Selected Publications

  • In vivo PET detection of lung micrometastasis by targeting endothelial VCAM-1. Int J Mol Sci, 2024.
  • Multi-institutional audit of FLASH and conventional dosimetry with a 3D-printed anatomically realistic mouse phantom. Int J Radiat Oncol Biol Phys, 2023.
  • Exploring deep learning for estimating the isoeffective dose of FLASH irradiation from mouse intestinal histological images. J Radiat Oncol Biol Phys, 2023.
  • Human enteroids as a tool to study conventional and ultra-high dose rate radiation. Integr Biol (Camb), 2023.
  • Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. J Clin Invest, 2023.

🏆 Awards & Honors

  • Recognition of Excellent Research: Aegean Conferences: 12th International Conference on Complement Therapeutics, Rhodes, Greece, 2019
  • Poster Prize: Aegean Conferences: 3rd International Conference for Tumor Microenvironment and Cellular Stress, Greece, Mykonos, 2014

🗣️ Conference Presentations

  • Oral Presentation: Demonstrating FLASH effectiveness against CONV dose rates, 34th ACRO Summit, Orlando, FL, March 2024
  • Poster Presentation: Anatomically Realistic 3D Printed Mouse Phantom for Multi-Institutional Benchmarking of FLASH and CONV Irradiation, 65th ASTRO Annual Meeting San Diego, USA, Oct 2023

📞 References

  • Prof. Billy W Loo Jr: Professor of Radiation Oncology (Radiation Therapy), Stanford University School of Medicine
  • Prof. Edward E Graves: Associate Professor of Radiation Oncology and Director of Molecular Imaging Program, Stanford University School of Medicine
  • Prof. Frederick M Dirbas: Associate Professor of Surgery (General Surgery), Stanford University School of Medicine

Dr. Stavros Melemenidis is a distinguished figure in radiation oncology, with a profound impact on preclinical radiotherapy and FLASH irradiation research. His contributions to innovative imaging techniques and his dedication to advancing cancer treatment methodologies are reflected in his extensive publication record and numerous accolades.

📊🔬Notable Publication:

 

 

 

 

Ms. Hao Li – Tumor Immunology – Young Scientist Award

Posted on by Pencis

Ms. Hao Li - Tumor Immunology - Young Scientist Award

First Hospital of China Medical University - China

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Li Hao began his academic journey at Dalian Medical University in September 2015, majoring in Immunology, Biochemistry, Surgery, and Internal Medicine. During this period from 2015 to 2020, he laid the foundational knowledge in the medical sciences that would serve as the basis for his future specialization. His undergraduate studies provided him with a comprehensive understanding of the human body's immune system, biochemistry, surgical techniques, and internal medicine.Li Hao pursued his Master's degree in Emergency Medicine and Molecular Biology at China Medical University. This advanced academic pursuit enabled him to delve deeper into specialized areas of medicine, focusing on emergency care and the molecular mechanisms underlying various medical conditions.

PROFESSIONAL ENDEAVORS

In May 2021, Li Hao started his professional career as a Resident Physician at the First Hospital of China Medical University. During his tenure from May 2021 to August 2021, he gained hands-on experience in clinical settings, honing his skills in medical records writing and cardiopulmonary resuscitation (CPR). This role allowed him to apply his theoretical knowledge from his undergraduate studies in a practical setting, preparing him for more specialized roles in the medical field.In June 2023, Li Hao transitioned to the role of an Assistant at the First Hospital of China Medical University, where he continues to work to the present day. As an Assistant, he has been involved in research projects and clinical work, further expanding his expertise and contributing to advancements in the medical field.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Li Hao's research interests are diverse and interdisciplinary, focusing on the areas of nanomaterials, hepatocellular carcinoma, and macrophage biology. His research aims to explore innovative approaches and treatments for these medical conditions, leveraging the latest advancements in molecular biology and emergency medicine.

IMPACT AND INFLUENCE

Li Hao's contributions to the medical field extend beyond his professional roles, as he actively engages in research and academic pursuits that have the potential to make a significant impact. His research in nanomaterials, hepatocellular carcinoma, and macrophage biology could lead to breakthroughs in treatment options and improve patient outcomes in these areas.

ACADEMIC SITES

Li Hao's academic achievements and research contributions have likely been cited in various scientific publications and conferences. His interdisciplinary research in nanomaterials, hepatocellular carcinoma, and macrophage biology demonstrates his commitment to advancing medical science and contributing valuable insights to the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As Li Hao continues to pursue his career in emergency medicine and molecular biology, his interdisciplinary research and clinical experience will undoubtedly leave a lasting legacy in the medical field. His dedication to improving patient care and advancing medical science positions him as a promising young professional with the potential to make significant contributions to the future of healthcare.

NOTABLE PUBLICATIONS

Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.  2024

Glutamate Chemical Exchange Saturation Transfer (GluCEST) MRI to Evaluate the Rapid Antidepressant Effects of Ketamine in the Hippocampus of Rat Depression Model. 2024 (1)

Preclinical multi-physiologic monitoring of immediate-early responses to diverse treatment strategies in breast cancer by optoacoustic imaging. 2024

Glutamate alterations in the premature infant brain during different gestational ages with glutamate chemical exchange saturation transfer imaging: a pilot study. 2023 (1)

Xenon inhalation attenuates neuronal injury and prevents epilepsy in febrile seizure Sprague-Dawley pups. 2023 (1)

 

Prof. Paolo De Simone – Oncology Therapy – Most Liked Article Award

Posted on by Pencis

Prof. Paolo De Simone - Oncology Therapy - Most Liked Article Award

UNIVERSITY OF PISA - Italy

Author Profile

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Paolo De Simone graduated summa cum laude in Medicine and Surgery from the University of Rome La Sapienza. His thesis was titled "Laparoscopic cholecystectomy in the treatment of gallstone lithiasis: prospective analysis of the results of our experience" under the supervision of Prof. Raffaello Cortesini.He earned his Specialist Diploma in General Surgery summa cum laude from the University of Rome “La Sapienza”. His thesis focused on "The role of laparoscopic surgery in the treatment of benign and malignant gastric pathologies" under the guidance of Prof. Raffaello Cortesini.Paolo De Simone achieved his PhD summa cum laude in Surgical Pathophysiology.

PROFESSIONAL ENDEAVORS

Registered in the Order of Doctors-Surgeons and Dentists of the Province of Rome with registration number 46702. He also qualified to practice the medical-surgical profession at the University of Rome “La Sapienza”. He served as a Foreign Resident-Assistant at the General Surgery Service of CHU André Vésale, Université Libre de Bruxelles, Montigny-Le-Tilleul, Belgium, and at the Thoracic and Vascular Surgery Service of the Hospital Avicenne, Bobigny, France. Paolo De Simone held several medical director positions:General Surgery Unit, Civil Hospital of Vittorio Veneto (TV),Organ Transplant Unit, San Salvatore Civil Hospital, L'Aquila,Service de Chirurgie Digestive, Hopital Erasme, Université Libre de Bruxelles, Brussels,University Liver Transplantology Unit, Pisa University Hospital.Currently, he is an Associate Professor of Surgery at the University of Pisa. He was elected Director of the School of Specialization in Surgery of the Digestive System and serves as Director of the Liver Surgery and Liver Transplant Unit, AOUP.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY THERAPY

Appointed as the Coordinator of the regional liver transplant program by DGRT of 17 December 2018, n. 1450. He also managed clinical, scientific, and educational coordination of terminal liver failure and liver transplantation (DG AOUP Resolution 852 of 09/20/2023).His research has covered areas like laparoscopic cholecystectomy, treatment of benign and malignant gastric pathologies, and liver transplantology.

IMPACT AND INFLUENCE

As Coordinator of the Liver Transplant Program of the Tuscany Region, he has significantly contributed to the advancement of liver transplantation in the region.

LEGACY AND FUTURE CONTRIBUTIONS

Paolo De Simone's legacy lies in his extensive contributions to the fields of general surgery, liver surgery, and liver transplantology. His future contributions are anticipated in enhancing liver transplant programs, furthering research in surgical pathophysiology, and mentoring the next generation of surgeons through his academic roles.

NOTABLE PUBLICATIONS

Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation.

First-in-human liver transplantation from a centenarian deceased donor after brain death.

Aging with a Liver Graft: Analysis of Very Long-Term Survivors after Liver Transplantation.

An Unexpected Case of Opisthorchis felineus Infection Revealed during Liver Transplantation.

An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients.

 

Dr. Francesco Raspagliesi – Gynecologic Oncology – Best Researcher Award

Posted on by Pencis

Dr. Francesco Raspagliesi - Gynecologic Oncology - Best Researcher Award

Fondazione IRCCS Istituto nazionale Tumori di Milano - Italy  

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Francesco Raspagliesi began his academic journey with a Degree in Medicine and Surgery from the University of Catania, Italy, which he completed on March 7, 1981. Following this foundational education, he obtained qualifications to practice medicine in 1981 and specialized in Obstetrics and Gynecology from the University of Catania in 1985 and 1988. These early academic pursuits laid the groundwork for his future professional endeavors in the field of gynecologic oncology.

PROFESSIONAL ENDEAVORS

From 1985 to 1992, Raspagliesi served as a Research Fellow at the Fondazione IRCCS Istituto Nazionale Tumori di Milano. He continued his professional growth at the same institution, becoming a Dirigente Medico di 1° Livello from 1992 to 1999 and advancing to Dirigente Medico di 2° Livello Gynecologic Oncology Unit Director from 1999 to 2019. His long-standing association with the Fondazione IRCCS Istituto Nazionale Tumori di Milano demonstrates his commitment and dedication to the field of gynecologic oncology and patient care.

CONTRIBUTIONS AND RESEARCH FOCUS ON GYNECOLOGIC ONCOLOGY

Throughout his career, Raspagliesi has made significant contributions to the field of Obstetrics and Gynecology. His research and clinical work have focused on gynecologic oncology, particularly in the treatment and management of gynecologic cancers. His expertise and leadership as the Gynecologic Oncology Unit Director have contributed to advancements in the diagnosis, treatment, and care of patients with gynecologic cancers.

IMPACT AND INFLUENCE

As a respected figure in the field of gynecologic oncology, Raspagliesi's work has had a profound impact on patient care, research, and education. His leadership roles and contributions to research have helped shape the way gynecologic cancers are treated and managed, influencing clinical practice and improving patient outcomes.

LEGACY AND FUTURE CONTRIBUTIONS

Francesco Raspagliesi's legacy in the field of Obstetrics and Gynecology is characterized by his dedication to patient care, leadership in gynecologic oncology, and contributions to research and education. His continued commitment to advancing the field through research, mentorship, and clinical practice ensures that his influence will be felt by future generations of gynecologic oncologists.

NOTABLE PUBLICATIONS

Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.  2024

Sentinel node mapping in high-intermediate and high-risk endometrial cancer: Analysis of 5-year oncologic outcomes. 2024

Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.  2024

Impact of Cold Ischemia on the Stability of 1H-MRS-Detected Metabolic Profiles of Ovarian Cancer Specimens. 2024

Concurrent Endometrial Cancer in Women with Atypical Endometrial Hyperplasia: What Is the Predictive Value of Patient Characteristics? (2) 2024

 

 

Medical Oncology

Posted on by Pencis

Medical Oncology

Introduction to Medical Oncology: Medical Oncology is a specialized branch of medicine dedicated to the diagnosis, treatment, and management of cancer. This field plays a pivotal role in improving the lives of cancer patients through various treatment modalities and cutting-edge research. Within the realm of Medical Oncology, several key subtopics are essential for understanding and addressing the complexities of cancer care:

Chemotherapy and Targeted Therapies: Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells, while targeted therapies focus on specific molecular abnormalities within cancer cells. Understanding these treatment options is crucial for medical oncologists to tailor therapies for individual patients.

Immunotherapy: Immunotherapy harnesses the body’s immune system to combat cancer. This groundbreaking approach has revolutionized cancer treatment by enhancing the body’s natural defenses against cancer cells.

Precision Medicine: Precision medicine in oncology involves customizing treatment plans based on a patient’s unique genetic and molecular profile. It allows for more personalized and effective cancer treatments, minimizing side effects.

Palliative Care: Palliative care in Medical Oncology is vital for improving the quality of life for cancer patients. It focuses on symptom management, pain relief, and emotional support to enhance patients’ overall well-being.

Clinical Trials and Research: Ongoing research and clinical trials are at the forefront of Medical Oncology. Investigating new treatments, therapies, and breakthroughs in cancer care is essential for improving patient outcomes and advancing the field.

These subtopics illustrate the multidimensional nature of Medical Oncology, where a comprehensive approach is taken to address the complexities of cancer treatment and patient care.